Cortistatin
A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.
Also referenced as: CST
Also appears in: Hormone · Immune
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Other. Also surfaces under Hormone, Immune for browsing and discovery.
CST
No FDA label signal · 727 trials · 8042 PubMed results
Current evidence for Cortistatin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Cortistatin has no clinical trials that name it and 8043 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What cortistatin is
Cortistatin is a neuropeptide related to somatostatin with research relevance in inflammation, neuroendocrine signaling, and cardiovascular biology.
Why it matters
It is a good example of a peptide that is scientifically interesting and biologically rich even though it is not a mainstream vendor-market name.
Regulatory context
Cortistatin is not FDA approved as a therapeutic peptide in the United States.
Practical reading note
Adding peptides like cortistatin helps keep the library from becoming only a catalog of the internet’s loudest compounds.